[1] Richette P, Bardin T. Gout[J]. Lancet,2010,375(9711): 318-328.
[2] Neogi T,Jansen T L,Dalbeth N,et al.2015 Gout Classification Criteria: an American College of Rheumatology/European League Against rheumatism Collaborative Initiative [J]. Arthritis Rheumatol,2015, 67: 2557-2568.
[3] 中华医学会风湿病学分会. 2016中国痛风诊疗指南[J]. 中华内科杂志, 2016, 55(11):892-899.
[4] 栗占国, 张学武. 漫话风湿:现代帝王病-痛风[M]. 上海:复旦大学出版社, 2015:178.
[5] Qing Y F, Zhang Q B, Zhou J G, et al.Changes in toll-like receptor (TLR)4-NFκB-IL1β signaling in male gout patients might be involved in the pathogenesis of primary gouty arthritis[J]. Rheumatol Int, 2014, 34(2): 213-220.
[6] Dumusc A, So A. Interleukin-1 as a therapeutic target in gout [J]. Curr Opin Rheumatol, 2015, 27(2): 156-163.
[7] Sivera F, Wechalekar M D, Andrés M. et al. Interleukin-1 inhibitors for acute gout[J]. Cochrane Database Syst Rev, 2014(9): 121-126.
[8] 曾学军. 2015年美国风湿病学会/欧洲抗风湿病联盟痛风分类标准解读[J]. 中华临床免疫和变态反应杂志, 2015, 9(4): 235-238.
[9] Reginato A M, Mount D B, Yang I, The genetics of hyperuricaemia and gout [J]. Nat Rev Rheumatol, 2012, 8(10): 610-621.
[10] Villaverde V, Rosario M P, Loza E, et al. Systematic review of the value of ultrasound and magnetic resonance musculoskeletal imaging in the evaluation of response to treatment of gout [J]. Reumatol Clin, 2014, 10(3):160-163.
[11] Naredo E, Uson J, Jiménez-Palop M. et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? [J]. Ann Rheum Dis, 2014, 73(8): 1522-1528.
[12] Peiteado D, Villalba A, Martín-Mola E, et al. Reduction but not disappearance of Doppler signal after two years of treatment for gout. Do we need a more intensive treatment? [J]. Ann Rheum Dis, 2015, 74(6):1072-1077.
[13] Bongartz T, Glazebrook K N, Kavros SJ, et al. Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study [J]. Clin Exp Rheumatol, 2015, 33(3):385-390.
[14] Ogdie A, Taylor W J, Weatherall M, et al. Imaging modalities for the classification of gout: systematic literature review and meta-analysis[J]. Ann Rheum Dis, 2015, 74(10): 1868-1874.
[15] Stamp L K. Safety profile of anti-gout agents: an update[J]. Curr Opin Rheumatol, 2014, 26(2): 162-168.
[16] Dalbeth N, Lauterio T J, Wolfe H R, et al. Mechanism of action of colchicines in the treatment of gout[J]. Clin Ther, 2014, 36(10): 1465-1479.
[17] Stamp L K, Barclay M L. How to prevent allopurinol hypersensitivity reactions? [J]. Rheumatology (Oxford), 2018, 57(suppl_1): i35-i41.
[18] Frampton J E. Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout [J]. Drugs, 2015, 75(4): 427-438.
[19] Edwards N L, So A. Emerging therapies for gout [J]. Rheum Dis Clin North Am, 2014, 40(2): 375-387.
[20] Schlesinger N. Anti-interleukin-1 therapy in the management of gout[J]. Curr Rheumatol Rep, 2014, 16(2): 398.
[21] Mitroulis I, Kambas K, Ritis K, et al. Neutrophils, IL-1β, and gout: is there a link? [J]. Semin Immunopathol, 2013, 35(4): 501-512.
[22] Kolasinski S L. Food, drink, and herbs: alternative therapies and gout [J]. Curr Rheumatol Rep, 2014, 16(4): 409.
[23] Burbage G. Gout: clinical presentation and management [J]. Nurs Stand, 2014, 29(2): 50-56.